Cargando…

A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?

Detalles Bibliográficos
Autor principal:	Furuse, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413480/ https://www.ncbi.nlm.nih.gov/pubmed/30704928 http://dx.doi.org/10.1016/j.ebiom.2019.01.039

Ejemplares similares

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Targeting tumour microenvironment, a FAKtual challenge in pancreatic cancer
por: Tolosa, Ezequiel J, et al.
Publicado: (2020)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines
por: Waissi, Waisse, et al.
Publicado: (2021)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
por: Hammel, Pascal, et al.
Publicado: (2020)

Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan
por: Furuse, Junji
Publicado: (2019)

Potential linkage between dipeptidyl peptidase‐4 inhibitor use and the risk of pancreatitis/pancreatic cancer
por: Shirakawa, Jun, et al.
Publicado: (2020)

PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session
por: Patel, Rajvi, et al.
Publicado: (2019)

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
por: Sunkara, Tejasvi, et al.
Publicado: (2022)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Adenosine in pancreatic cancer: Emerging combination therapies
por: Roth, Susanne, et al.
Publicado: (2019)

Pancreatic Cancer: Targeted Therapy Holds the Promise
por: Zhou, Zhijun, et al.
Publicado: (2021)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance
por: BU, CHIWEN, et al.
Publicado: (2023)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
por: Bayley, Rachel, et al.
Publicado: (2023)

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
por: Pishvaian, Michael J, et al.
Publicado: (2017)

Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival
por: Morganti, Alessio G., et al.
Publicado: (2019)

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
por: Okusaka, Takuji, et al.
Publicado: (2020)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

Loss of intratumoral macroscopic fat in renal angiomyolipoma following chemoradiation therapy for pancreatic cancer
por: Miller, Frank Howard, et al.
Publicado: (2016)

The case for a stratified application of targeted agents against pancreatic cancer
por: Bijlsma, Maarten F.
Publicado: (2021)

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
por: Wang, Yali, et al.
Publicado: (2021)

Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation
por: Cabrera, M. Carla, et al.
Publicado: (2014)

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer
por: Wittmann, David, et al.
Publicado: (2020)

Triple combination therapy for pancreatic cancer remodels stroma and improves survival
por: Vázquez-Arreguín, Karina, et al.
Publicado: (2023)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
por: Qiao, Yuan, et al.
Publicado: (2022)

Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer
por: Ashida, Reiko, et al.
Publicado: (2020)

PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation
por: IJff, Marloes, et al.
Publicado: (2021)

Familial Pancreatic Cancer: To Screen or not to Screen?
por: Vasen, Hans F.A., et al.
Publicado: (2015)

DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition
por: Viera, Talysa, et al.
Publicado: (2020)

Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
por: Galindo, José, et al.
Publicado: (2013)

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
por: YANG, XUELI, et al.
Publicado: (2015)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

2016 Gastrointestinal Cancers Symposium: update on pancreatic cancer
por: Russo, Suzanne, et al.
Publicado: (2016)

Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer
por: Wang, Charles X., et al.
Publicado: (2022)

Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer
por: Das, Rishi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0fgve74rgpupic3ncgif8vld9n